Goodwin advised BIVF, Novo and Evotec on the deal. Boehringer Ingelheim Venture Fund GmbH (“BIVF”), Novo Holdings REPAIR Impact Fund (“Novo”) and Evotec SE (“Evotec”) led...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here